Oil will never run out, but medical equipment is in short supply—Insights into the Middle East’s healthcare market from the United Arab Emirates.

The core GCC medical device market is projected to reach approximately US$8.3–8.4 billion by 2026; when including various medical consumables, the total market size could expand to US$15.3 billion. This growth is primarily driven by Saudi Arabia and the United Arab Emirates, which account for 52% and 28%, respectively.

In 2025, China’s exports of medical devices to the Middle East totaled US$3.484 billion, up 1.54% year on year. Saudi Arabia, the United Arab Emirates, and Turkey accounted for 60.53% of the total export value. Medical consumables made up over 43% of the total. The IVD segment was particularly robust: in the first half of 2025, exports of IVD instruments rose by 43.8%, while reagent sales increased by 23.3%.

These are not “trend forecasts,” but rather “established realities.”

In addition, there is an underlying logic that has been repeatedly underestimated: chronic disease.

The prevalence of type 2 diabetes in the MENA region is 16.2%, the highest globally. The prevalence of ASCVD in the Middle East is approximately 20.9%. In the United Arab Emirates, the 10-year cardiovascular disease risk estimate is 99.8%—nearly the entire population is at high risk.

This means that devices and consumables for blood glucose monitoring, medical imaging, interventional therapy, dialysis, and other applications are not merely market trends—they are essential, indispensable needs.

Add to this the Arab region’s population of 480 million—double its size compared with the 1990s—and the spillover effect of Dubai’s annual spending by international medical tourists, and you’ll see that demand is surging from all directions.

The Middle East is not “one market.” The six GCC countries each have their own independent regulatory frameworks, procurement practices, and distribution networks. Companies accustomed to CE certification often assume that a single certificate covers the entire European Union; however, in the GCC, a certificate issued by Saudi Arabia’s SFDA is not automatically recognized in the UAE, Kuwait, Qatar, or Oman.

However, registration and certification are merely the first hurdles. What truly gives Chinese companies headaches are the three issues that follow.

Many European and American brands have been deeply entrenched in the Middle East for decades, enjoying a firmly established reputation among physicians and procurement officials.

Chinese companies offer products with competitive specifications and more attractive pricing, yet the first question buyers typically ask is: “How many engineers do you have in Saudi Arabia?” At present, most Chinese firms can only secure contracts with small- and medium-sized private hospitals. Public‑sector hospital tenders impose stringent requirements—product registration certificates, ISO 13485 certification, local agent authorization, and a track record of supply over the past three years are all indispensable. Meanwhile, ESG and sustainability ratings are increasingly being factored into tendering processes, an area where Chinese companies generally lag behind.

In the Middle East, the combination of extreme heat and dusty conditions results in equipment failure rates that are inherently higher than in temperate regions. Slow response times for maintenance and insufficient spare parts are among the most common complaints from end users.

The prevailing situation among Chinese companies that have just entered the market is remote sales, coupled with a lack of local service networks. How to design differentiated products tailored to local needs and how to swiftly establish a localized support system are critical questions that must be addressed from the very outset.

The GCC has a unified registration system for pharmaceuticals, but not for medical devices.

• Saudi Arabia: Under the SFDA’s “Saudi Route,” MDMA submissions undergo TFA technical dossier evaluation, with a registration cycle of 6–18 months. The SAR (Saudi Authorized Representative) must be an independent legal entity; the registration certificate is held by the SAR, and a change of agent requires re‑registration.

• United Arab Emirates: Federal Decree No. 38 of 2024 establishes the EDE as the new registration authority. The MOHAP, DHA, and DOH operate in parallel, with a transition period of 3 to 12 months.

• Kuwait, Qatar, and Oman: Each maintains independent registration procedures, with a processing time of 6–12 months; they partially accept assessments and references from other countries but do not have formal mutual recognition.

• Bahrain: NHRA, 3–6 months; the only GCC country that accepts SFDA/MOHAP mutual recognition under the fast-track pathway.

In addition, Saudi Arabia mandates Arabic labeling, and products containing animal-derived ingredients must obtain Halal certification to clear customs. Furthermore, the boundaries between Saudi medical device classifications A, B, C, and D are unclear, and a single misclassification can result in months of wasted time.

When many people talk about expanding into the Middle East, their first instinct is to head to Saudi Arabia—because it’s the largest market.

However, Saudi Arabia is notorious for its high regulatory hurdles: SFDA registration typically takes 6 to 18 months from start to finish; the Saudi authorized representative must be an independent legal entity; and the registration certificate remains in the agent’s name—changing agents requires re‑registration.

Arabic labeling is mandatory; Halal certification is mandatory; category boundaries are unclear, and a single misclassification can waste several months.

By contrast, the United Arab Emirates is relatively straightforward.

First, let’s look at the market itself. The UAE healthcare market is the second-largest in the GCC and is projected to reach US$60 billion by 2030.

In 2023, Dubai attracted approximately 691,000 international medical tourists, with healthcare expenditures exceeding US$280 million. The United Arab Emirates is advancing the modernization of its healthcare system through the “We the UAE 2031” initiative, while Dubai, under the D33 agenda, continues to expand its medical infrastructure and attract healthcare investments.

But the UAE’s true value lies not merely in its market figures—it rests on three key factors.

The UAE EDE registration process takes 3 to 12 months, more than half as long as the Saudi SFDA’s. Federal Decree No. 38 of 2024 has harmonized the regulatory framework, ensuring clear rules and transparent procedures. For small and medium-sized enterprises, this translates into a tangible “time‑cost” advantage.

Dubai’s Jebel Ali Free Zone (JAFZA) and Dubai Healthcare City (DHCC) allow 100% foreign ownership, with zero tariffs, no corporate income tax, and no foreign‑exchange controls. By establishing a warehouse in JAFZA, your goods can serve the entire Middle East and Africa—Jebel Ali Port is the largest transshipment hub in the region, reaching East Africa in 3 to 5 days and West Africa in 7 to 10 days. Dubai International Airport connects to over 260 destinations worldwide: Riyadh is just 1.5 hours away, Cairo 3.5 hours, and Nairobi 5 hours—making it a strategic base that covers an entire continent.

In Dubai’s annual re-export trade, medical devices constitute a key product category. Many Chinese companies have established regional headquarters in the Dubai Free Zone, leveraging their UAE registration to expand into Saudi Arabia, Kuwait, Qatar, Oman, Bahrain, and even extend their reach to North and East Africa. While the UAE’s domestic market is approximately US$30 billion, the volume of medical devices re‑exported through Dubai to countries across the Middle East and Africa is several times larger than the local market size.

Once a foothold is established in the UAE, it becomes easier to leverage Dubai’s extensive distributor network. As one of the cities with the highest density of medical distributors worldwide, these distributors not only serve the UAE but often extend their reach to Saudi Arabia, Qatar, Oman, Kuwait, and even Egypt, Iraq, and Libya—making Dubai a gateway to the entire Middle East and North Africa region.

Now, an effective window of opportunity has already opened.

WHX Dubai 2027 is currently in the warm-up phase.

4,296 exhibiting companies

235,000 professional visitors

Covers 180+ countries

Intended transaction value: USD 3.9 billion

This is the report card it submitted in 2026.

A single exhibition encompasses the Middle East and extends its reach to neighboring regions.

WHX Dubai 2027 — The Must-Choose First Stop for Expanding into the Middle East

Scale effects plus an ecosystem help accelerate your global expansion.

As we’ve repeatedly emphasized, conquering a challenging market doesn’t just win you a market—it equips you with a capability.

When a market’s barriers to entry are so low that anyone can join, profits have long since been eroded. The barriers in the Middle East, by contrast, serve as a moat for early entrants.

Understanding diverse regulatory frameworks, navigating cultural diversity, and building a localized service network will enable you to enter your next market several times faster than your competitors.

The Middle Eastern market happens to be at an unmissable window of opportunity—when the rules have fully matured, distribution channels have become firmly established, and brand awareness has been thoroughly cultivated, If you try to enter the market again, the cost will no longer be today’s figure.